Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021
10 mars 2021 17h00 HE | Achilles Therapeutics
Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 London, UK 10 March 2021 – Achilles Therapeutics plc (“Achilles” or the “Company”), a...
Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States
01 mars 2021 18h26 HE | Achilles Therapeutics
Achilles Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States London, UK 1 March 2021 – Achilles Therapeutics plc (“Achilles” or the...
Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials
05 févr. 2021 02h00 HE | Achilles Therapeutics
Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials...
Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics Announces Additional Financing Plans
05 févr. 2021 01h00 HE | Achilles Therapeutics
Achilles Therapeutics Announces Additional Financing Plans London, UK 5 February 2021 – Achilles Therapeutics (“Achilles” or the “Company”), today announced that it expects to consider additional...
Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
08 janv. 2021 07h00 HE | Achilles Therapeutics
Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager London, UK 7 January 2021 – Achilles Therapeutics (“Achilles” or the “Company”), a clinical-stage biopharmaceutical...
Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications
07 déc. 2020 02h00 HE | Achilles Therapeutics
Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications Stevenage, UK 7 December 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company...
Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer
01 déc. 2020 07h00 HE | Achilles Therapeutics
Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer Stevenage, UK 1 December 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing...
Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer
01 déc. 2020 02h00 HE | Achilles Therapeutics
Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer Stevenage, UK 1 December 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing...
Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours
19 nov. 2020 07h00 HE | Achilles Therapeutics
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours - Financing includes...
Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours
19 nov. 2020 02h00 HE | Achilles Therapeutics
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours - Financing includes...